Program
gadoterate meglumine
Also written as “Dotarem”, “Gadoterate meglumine (Dotarem)” and “Gadoterate meglumine”.
Its studies are mostly in Carcinoma, Hepatocellular · Central Nervous System Diseases · Brain Neoplasms · Kidney Diseases · Renal Artery Obstruction, led by Guerbet.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Guerbet | 121 open or running | phase 4since Mar 4, 2008 | Mar 4, 2008 | Dec 31, 2027phase 3 · NCT07348640 |
Also a collaborator on its studies: Bracco Imaging.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 4, 2008First study: phase 4 study in Renal InsufficiencyFirst studyNCT00650845 · 135 enrolled · Belgium, France, Italy and more
- Feb 16, 2009Phase 3 study in Renal Artery ObstructionNCT00845702 · 33 enrolled · United States
- Sep 17, 2009Phase 3 study in Kidney DiseasesNCT00980681 · 13 enrolled · United States
- Nov 9, 20092 phase 3 studies in Cerebral Arterial DiseasesNCT01010932, NCT01012674
- Dec 3, 2009Phase 4 study in Peripheral Arterial DiseaseNCT01026389 · 189 enrolled · Austria
- Sep 28, 2010Phase 3 study in Central Nervous System DiseasesNCT01211873 · 416 enrolled · United States, Argentina, Austria and more
- Oct 3, 2011Phase 1 study in Kidney Failure, ChronicNCT01449266 · 10 enrolled · Belgium
- Nov 6, 2012Phase 4 study in Carcinoma, HepatocellularNCT01806740 · 37 enrolled · Korea, Republic of
- Jan 10, 2014Phase 4 study in Brain NeoplasmsNCT02034708 · 279 enrolled · United States, Colombia, Korea, Republic of and more
- Mar 11, 2015Phase 4 study in Magnetic Resonance ImagingNCT02411201 · 51 enrolled · Austria, France, Hungary and more
- Jan 15, 2026Phase 3 study in Steno-occlusive DiseaseNCT07348640 · 315 planned · United States, Canada, Czechia and more
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Steno-occlusive DiseaseNCT07348640
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07348640Steno-occlusive Disease · United States, Canada, Czechia and more | 3 | Recruiting | Dec 31, 2027 | 315 |
| NCT02411201Magnetic Resonance Imaging · Austria, France, Hungary and more | 4 | Completed | Oct 2015 | 51 |
| NCT02034708Brain Neoplasms · United States, Colombia, Korea, Republic of and more | 4 | Completed | Sep 2015 | 279 |
| NCT01806740Carcinoma, Hepatocellular · Korea, Republic of | 4 | Terminated | Oct 12, 2015 | 37 |
| NCT01449266Kidney Failure, Chronic · Belgium | 1 | Completed | Mar 2012 | 10 |
| NCT01211873Central Nervous System Diseases · United States, Argentina, Austria and more | 3 | Completed | Nov 2011 | 416 |
| NCT01026389Peripheral Arterial Disease · Austria | 4 | Completed | Jun 2011 | 189 |
| NCT01012674Cerebral Arterial Diseases · United States | 3 | Completed | Dec 2010 | 211 |
| NCT01010932Cerebral Arterial Diseases · United States | 3 | Completed | Dec 2010 | 222 |
| NCT00980681Kidney Diseases · United States | 3 | Terminated | Dec 2010 | 13 |
| NCT00845702Renal Artery Obstruction · United States | 3 | Terminated | Feb 2010 | 33 |
| NCT00650845Renal Insufficiency · Belgium, France, Italy and more | 4 | Completed | May 2011 | 135 |
How it is read
Names in the registry
- “Dotarem”, 4 entries
- “Gadoterate meglumine (Dotarem)”, 2 entries
- “Gadoterate meglumine”, 1 entry
- “Dotarem (gadoterate meglumine)”, 1 entry
- “DOTAREM”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
- Central Nervous System Diseases, 1 study
- Brain Neoplasms, 1 study
- Kidney Diseases, 1 study
- Renal Artery Obstruction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.